On November 4, 2019, Abeona Therapeutics Inc. (the "Company") reported that it entered into the First Amendment to License Agreement (the "First Amendment") with REGENXBIO Inc. (the "Licensor"), which amends the license agreement between the Company and the Licensor entered into on November 4, 2018 (the "Original Agreement," and as amended by the First Amendment, the "Agreement") (Filing, 8-K, Abeona Therapeutics, NOV 7, 2019, View Source [SID1234550638]). As disclosed previously, the Agreement grants the Company an exclusive, worldwide commercial license, with rights to sublicense, to the NAV AAV9 vector for the treatment of the certain indications in humans by in vivo gene therapy. The First Amendment amends the Original Agreement solely to replace the $10 million payment due to the Licensor within one year of the Original Agreement with a provision stating that the Licensor shall receive $3 million within one year of the Original Agreement and another $8 million no later than April 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!